Parker-Hannifin is no longer just a well-run motion-and-control compounder. The company closed a cash filtration acquisition of more than $9 billion one week after reporting a record fiscal year, and the equity now has to carry both the organic machine and the digestion of that deal. Management already raised the long-horizon adjusted margin target to 30% after beating the prior 27% mark a few years early. The market is treating that raise as confirmation that the Win Strategy still has room. The harder read is whether a premium multiple survives a sudden jump in term-loan leverage.
The fiscal year itself was a genuine operating year, not a financial-engineering year. Organic sales rose about 7% and aerospace did the heavy lifting, while North American and international industrial units both turned positive as factory activity broadened. Cash conversion stayed above 100% and backlog set a new high. Reported earnings grew much more slowly than sales because the tax rate normalized after a prior-year valuation-allowance release, and a one-time tariff refund of $84 million flattered fourth-quarter cost of sales. Adjusted earnings tell the cleaner story, and that is the number the market is using.
What remains unresolved is the capital-structure reset that does not yet sit on the year-end balance sheet. Parker drew nearly $8 billion of term loans in mid-August to fund Filtration Group, and a pending aerospace tuck-in near $3 billion still needs to close. Guidance for the new year excludes both deals and still asks for mid-to-high single-digit organic growth plus another increment of margin. The investment debate is whether those organic numbers, plus promised filtration synergies, justify a mid-twenties forward multiple after leverage steps up. The next few prints decide if the transformation is compounding or just larger.